Track topics on Twitter Track topics that are important to you
GUELPH, ON, Aug. 10, 2017 /PRNewswire/ – BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several new orders totaling $5 million. The orders are for air emission abatement projects in North America, the Middle East and China.
"The value our customers perceive in the engineered approach BIOREM follows is apparent in the strong booking rate for 2017," said Derek S. Webb, President and Chief Executive Officer. "The key deciding factors for their purchasing decisions is based on our experience, our integrity and our long term reliable performance."
"Of particular note, we are pleased to have secured our first high profile order from Puhua Industries in China, which is a subsidiary of our new strategic investor, TUS Holdings Group ("TUS"). This represents a significant milestone for the Company as we leverage TUS's considerable resources to capitalize on the world's largest market for environmental goods."
The Company's 2017 order bookings to date total $17.5 million compared to $7.6 million of orders booked in the first seven months of 2016 and the current order backlog of $23 million is $5.9 million or 35% greater than the order backlog of $17.1 million on June 30, 2016.
About BIOREM Inc.BIOREM is a leading clean technology company that designs, manufactures and distributes a comprehensive line of high-efficiency air emissions control systems used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). With sales and manufacturing offices across the continent, a dedicated research facility, a worldwide sales representative network and more than 1000 installed systems worldwide, BIOREM offers state-of-the-art technology-based products and peace of mind for municipalities, industrial companies and their surrounding communities. Additional information on BIOREM is available on our website at www.biorem.biz.
SOURCE Biorem Inc.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...